Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
TA Wichelmann, S Abdulmujeeb… - Alimentary …, 2021 - Wiley Online Library
Background Bevacizumab is used in the treatment of advanced malignancies and has a
“black box” warning for gastrointestinal perforations. Despite this known side effect, there are …
“black box” warning for gastrointestinal perforations. Despite this known side effect, there are …
The risk and clinical implications of antibiotic-associated acute kidney injury: a review of the clinical data for agents with signals from the food and drug administration's …
Antibiotic-associated acute kidney injury (AA-AKI) is quite common, especially among
hospitalized patients; however, little is known about risk factors or mechanisms of why AA …
hospitalized patients; however, little is known about risk factors or mechanisms of why AA …
Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk of Clostridium difficile Infection Associated with …
D Li, Y Song, Z Bai, X Xi, F Liu, Y Zhang, C Qin, D Du… - Antibiotics, 2023 - mdpi.com
Antibacterial drug exposure (ADE) is a well-known potential risk factor for Clostridium
difficile infection (CDI), but it remains controversial which certain antibacterial drugs are …
difficile infection (CDI), but it remains controversial which certain antibacterial drugs are …
Identification of signal of clindamycin associated renal failure acute: a disproportionality analysis
F Javed, A Kumar - Current Drug Safety, 2024 - ingentaconnect.com
Background: Early signal detection from post-marketing studies play a vital role in the safety
of patients. Recent case reports have indicated the association of clindamycin with renal …
of patients. Recent case reports have indicated the association of clindamycin with renal …
The severity of adverse drug reactions and their influencing factors based on the ADR monitoring center of Henan Province
Z Yan, Z Feng, Z Jiao, C Chen, G Wang, D Feng - Scientific Reports, 2021 - nature.com
Adverse drug reactions (ADRs) may be a serious public health problem and have received
widespread attention in recent years. This study has analyzed the factors leading to the …
widespread attention in recent years. This study has analyzed the factors leading to the …
[HTML][HTML] Prevalence of polymyxin-induced nephrotoxicity and its predictors in critically ill adult patients: A meta-analysis
JL Wang, BX Xiang, XL Song, RM Que… - World Journal of …, 2022 - ncbi.nlm.nih.gov
BACKGROUND Polymyxin-induced nephrotoxicity is a major safety concern in clinical
practice due to long-term adverse outcomes and high mortality. AIM To conducted a …
practice due to long-term adverse outcomes and high mortality. AIM To conducted a …
Hypoglycemia associated with antibiotics alone and in combination with sulfonylureas and meglitinides: an epidemiologic surveillance study of the FDA Adverse …
Introduction Fluoroquinolones, clarithromycin, linezolid, tigecycline, cefditoren, doxycycline,
and trimethoprim–sulfamethoxazole are known to be associated with hypoglycemia, but few …
and trimethoprim–sulfamethoxazole are known to be associated with hypoglycemia, but few …
Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database
P Chen, J Zhu, Y Xu, Q Huang, J Su, Z Gao, M Feng - BMC nephrology, 2023 - Springer
Background Several risk factors of immune checkpoint inhibitors (ICIs)-associated acute
kidney injury (AKI) have been reported sporadically. To identify the risk factors of ICIs …
kidney injury (AKI) have been reported sporadically. To identify the risk factors of ICIs …
Acute kidney injury following the use of different proton pump inhibitor regimens: a real‐world analysis of post‐marketing surveillance data
G Chen, LJ Ning, Y Qin, B Zhao… - Journal of …, 2021 - Wiley Online Library
Abstract Background and Aim Recent evidence has concerned acute kidney injury (AKI)
after the proton pump inhibitor (PPI) application. There are few real‐world studies to …
after the proton pump inhibitor (PPI) application. There are few real‐world studies to …
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
M Gatti, E Raschi, F De Ponti - European Journal of Clinical Microbiology & …, 2021 - Springer
The purpose of this study is to characterize adverse events (AEs) of clinical interest reported
with ceftolozane-tazobactam and ceftazidime-avibactam, as an aid in monitoring patients …
with ceftolozane-tazobactam and ceftazidime-avibactam, as an aid in monitoring patients …